At a glance
ClinicalIndex Comparison RecordN/ACompleted· 502 enrolled
Drug / intervention
Alfacalcidoldrug
Likely dose
Alfacalcidol 1 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness Between Daily Versus Pulse Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients: A Randomized Controlled Trial and Multicenter Study
Phramongkutklao College of Medicine and Hospital·interventional·Posted Sep 9, 2016·Updated May 31, 2017
In Brief
A clinical study evaluating Alfacalcidol for Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis. Completed, enrolled 502 participants.
Detailed Summary
Primary objective was to evaluate the efficacy between daily and pulse oral alfacalcidol treatment of SHPT in chronic hemodialysis patients, a 12-week treatment. Secondary objective was to observe the adverse effects between these two treatment regimens.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
Primary CompletionOct 2015
Study CompletionJan 2016
First PostedSep 2016
TodayJul 2026
First PostedSep 9, 2016
Enrollment StartJan 1, 2015
Primary CompletionOct 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.8 years ago
Interventions
Alfacalcidoldrug
Alfacalcidol 1 microgram/capsule